Table 2.
Multiple linear regression analyses of the association between homocysteine abundance and annual decline in eGFR. as a dependent variable in type 2 diabetic patients
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| Homocysteine (μmol/L)* | 0.393 (<0.001) | 0.262 (0.013) | 0.254 (0.015) |
| Duration of diabetes (years) | 0.022 (0.816) | 0.04 (0.686) | |
| HbA1c (%) | 0.005 (0.954) | 0.003 (0.975) | |
| HDL (mg/dL) | -0.004 (0.968) | -0.016 (0.883) | |
| eGFR (ml/min/1.73 m2) | 0.138 (0.121) | 0.131 (0.173) | |
| u-ACR (ng/mg)* | 0.295 (0.01) | 0.289 (0.011) | |
| Hypoglycemic agents, (%) | 0.146 (0.13) | 0.142 (0.168) | |
| Antihypertensive agents, (%) | -0.125 (0.244) | -0.156 (0.172) | |
| Age (years) | -0.01 (0.921) | ||
| Gender (male/female) | 0.072 (0.459) | ||
| BMI (kg/m2) | 0.099 (0.331) | ||
| SBP (mmHg) | 0.098 (0.368) | ||
| DBP (mmHg) | -0.168 (0.161) | ||
| Triglyceride (mg/dL)* | 0.039 (0.699) | ||
| LDL (mg/dL) | 0.055 (0.569) |
Note: Annual decline in eGFR was used as a dependent variable in the regression. Model 1: unadjusted; Model 2: adjusted for variables significantly associated with albuminuria status in Table 1; Model 3: adjusted for all variables tested. Association between different variables and the annual decline in eGFR are shown as Standard β (p-value).
*
Log transformed value was used in the model.